Literature DB >> 33952470

Contribution of Interleukin-10 Genotype to Triple Negative Breast Cancer Risk.

Kai-Yuan Chen1,2,3, Wei-Ching Chien4, Jiuan-Miaw Liao5, Chia-Wen Tsai1,6, Wen-Shin Chang1,6, Chen-Hsien Su6, Shih-Wei Hsu1,6, Hwei-Chung Wang7, DA-Tian Bau8,6,9.   

Abstract

BACKGROUND/AIM: Triple negative breast cancer (TNBC) is characterized by increased recurrence and poor survival. Mounting evidence suggests that interleukin-10 (IL-10) plays a role in carcinogenesis, however, little is known about the contribution of IL-10 to TNBC. The study evaluated the contribution of IL-10 promoter A-1082G (rs1800896), T-819C (rs3021097), A-592C (rs1800872) genotypes to the risk of TNBC.
MATERIALS AND METHODS: IL-10 genotypes were examined among 1,232 breast cancer patients and 1,232 controls and evaluated.
RESULTS: The percentages of AG and GG for IL-10 A-1082G genotypes were higher in the breast cancer patient group than in the control group. The GG genotype carriers were of higher risk for breast cancer [odds ratio (OR)=2.02, 95% confidence interval (CI)=1.28-3.21, p=0.0021]. Interestingly, G allele carriers were of higher risk of TNBC (OR=1.25, 95%CI=1.07-1.46, p=0.0050).
CONCLUSION: The G allele of IL-10 A-1082G genotype may serve as a predictor for TNBC risk. The finding should be validated in other populations.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; Taiwan; genotype; interleukin-10; polymorphism

Year:  2021        PMID: 33952470     DOI: 10.21873/anticanres.15020

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Association of Matrix Metalloproteinase-1 Genotypes With Bladder Cancer Risk.

Authors:  Cheng-Hsi Liao; Chia-Wen Tsai; Wen-Shin Chang; Zhi-Hong Wang; Chi-Li Gong; Hsi-Chin Wu; Bo-Ren Wang; Shih-Wei Hsu; Wen-Chin Huang; Te-Chun Shen; DA-Tian Bau
Journal:  In Vivo       Date:  2021 Sep-Oct       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.